Novartis to invest $100M to develop antimalarials - MarketWatch — Nigeria Today
Pages Navigation Menu

Latest and breaking news, sports and all that is trending today

Novartis to invest $100M to develop antimalarials – MarketWatch


Week Herald

Novartis to invest $100M to develop antimalarials
MarketWatch
Novartis AG (NOVN.EB) said Tuesday that it will invest more than $100 million in the next five years in the research and development of the next-generation antimalarials. The investment will focus on treatments to tackle resistance to antimalarials
Novartis (NOVN) Given a CHF 98 Price Target by Jefferies Group AnalystsThe Ledger Gazette
Novartis AG (NOVN) Receives CHF 88.88 Consensus PT from AnalystsMacon Daily
Novartis AG (NOVN) Given Average Rating of “Hold” by BrokeragesWeek Herald
Yahoo Singapore News –GlobeNewswire (press release)
all 7 news articles »

Do you have something awesome to share with the world? Click here to share

Do you ever have any question about anything you wish to ask and get answer? Click here to ask

Follow us on twitter @NigeriaTodayNG

Also, Like us on facebook

This post was syndicated from Business - Google News. Click here to read the full text on the original website.

Comments

Be the First to Comment!

avatar
  Subscribe  
Notify of
Download the Nigeria Today app from Play store. Click here download now
Hello. Add your message here.